Company Seeks Regulatory Approval To Market Dolutegravir As HIV Treatment For Babies And Children
December 16, 2019
Reuters (12/13, Kelland) reported GlaxoSmithKline’s ViiV Healthcare is seeking regulatory approval “to market its HIV drug dolutegravir in a formulation designed to be easier for babies and children who are living with the virus to swallow.” The article s...